Análise de eficácia de acordo com valores de TMB no CheckMate 9LA

O tumor mutation burden (TMB) está potencialmente associado à eficácia clínica dos inibidores de correceptores imunes. Durante o ELCC 2022, foram apresentados os dados de eficácia da combinação de nivolumabe + ipilimumabe + quimioterapia segundo os valores de TMB tanto do tecido tumoral quanto do sangue dos pacientes.

PDF) Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review

CheckMate 9LA: TMB and immune checkpoint inhibitor efficacy

Tratamiento inicial de mNSCLC: visión panorámica

Long Term Durability and Safety of Dual IO in NSCLC

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy

Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC - Medical Conferences

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations - ScienceDirect

PDF) Perspectivas da imunoterapia em pacientes com câncer de pulmão metastático

PDF) Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations: Tumor mutational burden in NSCLC

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes - ScienceDirect